Helicos Unveils 'Early Access' Availability of tSMS™ Technologies
News Jan 13, 2006
Helicos BioSciences has announced that it would begin partnering with a selected group of experimental researchers, providing access to its True Single Molecule Sequencing (tSMS™) technologies and techniques in support of research projects.
Helicos' "Early Access" partners may publish their findings from utilizing tSMS™ technologies, as well as present at scientific conferences.
Stanley N. Lapidus, President and CEO of Helicos BioSciences, said, "We are very proud to begin providing access to applications in tSMS™ to a small group of innovative research partners."
"This marks the first time in history that tSMS™ based applications will be open to the experimental community."
He added, "Our intention is to work closely with top researchers and thought leaders to demonstrate the full advantages of leveraging tSMS™ in unlocking experimental possibilities that were inconceivable up to now."
"We look forward to very intriguing and compelling results from these collaborations."
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.